GSK Acquires Phase III-Ready Efimosfermin for $1.2 Billion in Bid to Transform Steatotic Liver Disease Treatment GSK has announced a major strategic acquisition in the field of hepatology, entering into…
FDA Approves Merck’s WELIREG® (belzutifan) for Advanced Pheochromocytoma and Paraganglioma in Patients 12 Years and Older, Marking a New Era in Treatment of Rare Neuroendocrine Tumors Merck, known as MSD…
AbbVie and ADARx Partner to Advance Next-Generation siRNA Therapies Across Neuroscience, Immunology, and Oncology in Multibillion-Dollar Collaboration AbbVie, a global biopharmaceutical leader known for its portfolio of therapies in immunology,…
AbbVie Gains First Solid Tumor FDA Approval With EMRELIS™ for High c-Met Overexpressing Advanced NSCLC AbbVie has achieved a key milestone in its oncology pipeline with the announcement that the…
Novo Nordisk and Septerna Forge $2.2 Billion Global Alliance to Develop Oral Small Molecule Therapies for Obesity and Cardiometabolic Diseases In a significant expansion of its research and development pipeline,…
WHO Establishes Expert Surgical Sub-Group to Develop Global Guidelines for Caesarean Section Practices Caesarean section, often referred to as C-section, has become the most common major abdominal surgery performed across…
Sarepta’s ELEVIDYS Gene Therapy Gains Landmark Approval in Japan for Duchenne Muscular Dystrophy Sarepta Therapeutics, a biotechnology leader in precision genetic medicine for rare diseases, has announced a significant regulatory…
Legend Biotech Reports Strong First Quarter 2025 Performance and Strategic Milestones as CARVYKTI® Continues to Lead in Multiple Myeloma Legend Biotech Corporation, a global frontrunner in the field of cell…
WuXi Biologics Ireland: Pioneering Sustainable Biomanufacturing Through Purpose-Driven Innovation In an era where sustainability has become a defining metric of corporate integrity and resilience, WuXi Biologics Ireland stands out as…
UCB Highlights Robust Data on Generalized Myasthenia Gravis Therapies at 15th MGFA International Conference, Reinforcing Commitment to Patient-Centered Innovation UCB,a global biopharmaceutical leader specializing in immunology and neurology, has announced…
CMS Prepares Third Cycle of Drug Price Negotiations Under IRA as Trump Administration Revives Push to Lower U.S. Prescription Costs In a move that signals the growing momentum of federal…
Bayer Reaffirms 2025 Outlook Following Robust First-Quarter Performance, Showcases Strength in Pharmaceuticals and Strategic Advancements in Crop Science Bayer AG has started 2025 with a strong operational footing, underscoring confidence…